Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Return on Sales (2023 - 2025)

Entrada Therapeutics has reported Return on Sales over the past 3 years, most recently at 30.13% for Q4 2025.

  • Quarterly results put Return on Sales at 30.13% for Q4 2025, down 3016.0% from a year ago — trailing twelve months through Dec 2025 was 5.66% (down 597.0% YoY), and the annual figure for FY2025 was 5.65%, down 597.0%.
  • Return on Sales for Q4 2025 was 30.13% at Entrada Therapeutics, down from 27.37% in the prior quarter.
  • Over the last five years, Return on Sales for TRDA hit a ceiling of 0.81% in Q3 2023 and a floor of 30.13% in Q4 2025.
  • Median Return on Sales over the past 3 years was 0.49% (2023), compared with a mean of 6.77%.
  • Biggest five-year swings in Return on Sales: soared 201bps in 2024 and later tumbled -3016bps in 2025.
  • Entrada Therapeutics' Return on Sales stood at 0.23% in 2023, then skyrocketed by 113bps to 0.03% in 2024, then plummeted by -104824bps to 30.13% in 2025.
  • The last three reported values for Return on Sales were 30.13% (Q4 2025), 27.37% (Q3 2025), and 22.12% (Q2 2025) per Business Quant data.